**Abstract**

This two-part section helps the reader to achieve a better understanding of how cannabis works as a viable medication for the endocannabinoid system (ECS) and central nervous system (CNS) in humans by identifying individual synergies between cannabinoids, or cannabinoids and terpenes in their journey through the ECS and CNS in various mammalian patient indicators to unmask this paradoxical effect. The specific biphasic/ paradoxical manner in question was researched and inevitably identifies cannabis use that manipulates tryptophan uptake, serotonin release, and dopamine actuation. Therefore, a patient's diet may demand a higher tryptophan and dopa-L supplementation to avoid a paradoxical agitation on the receptor level. This chapter explains the pathology of how cannabis consistently reacts in the ECS for every individual, only separated by metabolism and disruption/trauma in the ECS and CNS, implying that there was no found paradoxical effect existing in cannabis, but in the patient, and thus is perceived the same in every individual, only mediated by metabolism, environment (surroundings), and the exception for individuals who process stimulants and tryptophan and/or serotonin in a disrupted manner causing a perceived paradoxical effect or the build-up to and/or what will be referred to as ASR/ATD. The cannabis industry, growers/breeders, interpeners/cannabis sommeliers/bud tenders, and dispensaries need to continue to constantly strive for more knowledge, just as the researchers and FDA need to continue their work to understand the benefits of cannabis, and most importantly, all must work together to remove cannabis from the Schedule I and Schedule 2 classification.

**Keywords:** advanced synergistic serotonin release (ASSR/ASR), advanced tryptophan depletion (ATD), Endo-cannabinoid system (ECS), central nervous system (CNS), psychoactive (PA), non psychoactive (N-PA), Cannabigerol (CBG), Tetrahydrocannabinol (THC), Tetrahydrocannabinolic acid (THCA), Tetrahydrocannabivarin (THC-V), Cannabinol (CBN), Cannabichromene (CBC), Cannabielsoin (CBE), Cannabicyclol (CBL), Cannabidiol (CBD), Cannabidiolic acid (CBDA), Cannabidivarin (CBDV), broad leaf marijuana (BLM), broad leaf marijuana dominant (BLMD), medium leaf marijuana (MLM), narrow leaf marijuana dominant (NLMD), narrow leaf marijuana (NLM), cannabinoid receptor type1 (CB1), cannabinoid receptor type 2 (CB2), Vanilloid receptor 1 (TRPV1), transient receptor

potential Ankyrin 1(TRPA1), γ-Aminobutyric acid (GABBA-A), Hydroxy-Tryptamine (5-HT), transient receptor potential cation channel, subfamily V, member 3 (TRPV3), attention deficit hyperactivity disorder (ADHD), γ-Aminobutyric acid (GABAA)
